EUVIMEDEUVIMED entdecken
Crossref

Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti–PD-1 efficacy in colorectal cancer

Siqi Chen, Qishan Liu, Shubiao Ye, Jing Yu, Yongxin Xie, Yuhai Yuan, Jianning Song, Yaqing Du, Min Li, Xueli Zhang, Yanping Ma, Zhensen Lin und 9 weitere

Science Translational Medicine · 18.11.2026 · 18 (876)

DOI: 10.1126/scitranslmed.aed2106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 18.11.2026. Verfasst von Siqi Chen und 20 weiteren Autor:innen. Die Arbeit nennt 77 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangzhou Municipal Science and Technology Project, Natural Science Foundation of Guangdong Province.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Loss of major histocompatibility complex class I (MHC-I) antigen presentation in tumor cells drives immune evasion and resistance to immune checkpoint blockade (ICB) in colorectal cancer (CRC). To identify therapeutic targets reversing this, we conducted fluorescence-activated cell sorting–based CRISPR activation screens using a druggable genome library and identified folate receptor α (FOLR1) as a top negative regulator. FOLR1 was heterogeneously expressed in CRC tumors but undetectable in adjacent normal tissues. High expression of FOLR1 predicted a poor ICB response, enhanced cancer stemness, and unfavorable patient outcomes. Functional assays showed that FOLR1 promoted CRC stemness–associated properties and fostered an immunosuppressive tumor microenvironment (TME) with impaired CD8 + T cell infiltration and cytotoxicity, thereby driving tumor progression. Proteomic analyses revealed that FOLR1 stabilized the lactyltransferase AARS1 (alanyl-tRNA synthetase 1), which lactylated signal transducer and activator of transcription 1 (STAT1) at lysine-193 (K193), facilitating its interaction with TCPTP (T cell protein-tyrosine phosphatase) and inducing STAT1 dephosphorylation at tyrosine-701. Consequently, impaired STAT1 signaling down-regulated MHC-I and up-regulated MYC proto-oncogene protein (c-MYC), facilitating evasion of T cell surveillance and enhancing cancer stemness. The anti-FOLR1 antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) exhibited potent activity against FOLR1-positive CRC cells, reprogramming the TME to an immune-active status. Combining IMGN853 with anti–PD-1 (programmed cell death protein–1) therapy boosted antitumor immunity, sensitized tumors to immunotherapy, and induced robust tumor regression in vivo. Our findings support anti-FOLR1 ADC as a clinically actionable approach to overcome immune evasion and unlock immunotherapy efficacy in CRC.

Förderung

  • National Natural Science Foundation of China
  • Guangzhou Municipal Science and Technology Project
  • Natural Science Foundation of Guangdong Province
  • National key R&D program of China
  • Fundamental Research Funds for the Central Universities, Sun Yat-sen University
  • the program of Guangdong Provincial Clinical Research Center for Digestive Diseases, National Key Clinical Discipline

Zitieren

APA

Chen, S., Liu, Q., Ye, S., Yu, J., Xie, Y., Yuan, Y., Song, J., Du, Y., Li, M., Zhang, X., Ma, Y., Lin, Z., Zhang, Y., Guan, X., He, G., Jiang, C., Fang, X., He, X., Li, L., …, & Yan, Q. (2026). Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti–PD-1 efficacy in colorectal cancer. Science Translational Medicine, 18(876). https://doi.org/10.1126/scitranslmed.aed2106

Vancouver

Chen S, Liu Q, Ye S, Yu J, Xie Y, Yuan Y, et al. Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti–PD-1 efficacy in colorectal cancer. Science Translational Medicine. 2026;18(876). doi:10.1126/scitranslmed.aed2106

BibTeX
@article{Chen2026,
  author = {Chen, Siqi and Liu, Qishan and Ye, Shubiao and Yu, Jing and Xie, Yongxin and Yuan, Yuhai and Song, Jianning and Du, Yaqing and Li, Min and Zhang, Xueli and Ma, Yanping and Lin, Zhensen and Zhang, Yu and Guan, Xin-Yuan and He, Guiwei and Jiang, Chen and Fang, Xiaona and He, Xiaosheng and Li, Lei and Lan, Ping and Yan, Qian},
  title = {Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti–PD-1 efficacy in colorectal cancer},
  journal = {Science Translational Medicine},
  year = {2026},
  volume = {18},
  number = {876},
  doi = {10.1126/scitranslmed.aed2106}
}
Kostenlos starten →